Comparison of a selective STAT3 inhibitor with a dual STAT3/STAT1 inhibitor using a dextran sulfate sodium murine colitis model: new insight into the debate on selectivity.

Fiche publication

Date publication

avril 2024

Journal

Annals of gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Pr BEDUNEAU Arnaud

Tous les auteurs :
Moulari B, Pallandre JR, Béduneau A, Borg C, Pellequer Y, Pudlo M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38779644

Résumé

Recent advances in the treatment of inflammatory bowel disease include antitumor necrosis factor antibodies and the Janus kinase inhibitor tofacitinib, approved for ulcerative colitis. Janus kinase recruits signal transducers and activators of transcriptions (STAT), which are promising targets in inflammatory bowel diseases. However few inhibitors have been evaluated, and their selectivity with respect to STAT1 and STAT3 remains controversial. Here, we investigated the therapeutic potential of a selective inhibitor vs. a non-selective, closely related compound, in a dextran sulfate sodium (DSS) murine colitis model.